These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 32190776)

  • 1. Hepatobiliary cancers and immunotherapy: where are we now and where are we heading?
    Zayac A; Almhanna K
    Transl Gastroenterol Hepatol; 2020; 5():8. PubMed ID: 32190776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Esophageal, gastric cancer and immunotherapy: small steps in the right direction?
    Zayac A; Almhanna K
    Transl Gastroenterol Hepatol; 2020; 5():9. PubMed ID: 32190777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities.
    Zhang X; Wu T; Cai X; Dong J; Xia C; Zhou Y; Ding R; Yang R; Tan J; Zhang L; Zhang Y; Wang Y; Dong C; Li Y
    Front Immunol; 2022; 13():795972. PubMed ID: 35371084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances of immunotherapy for biliary tract cancer.
    Rizzo A; Ricci AD; Brandi G
    Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):527-536. PubMed ID: 33215952
    [No Abstract]   [Full Text] [Related]  

  • 5. Current and emerging immunotherapeutic approaches for biliary tract cancers.
    Yuan ZG; Zeng TM; Tao CJ
    Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):440-449. PubMed ID: 36115807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma.
    Inokuchi J; Eto M
    Cancer Manag Res; 2019; 11():4519-4528. PubMed ID: 31191013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of immunotherapy in advanced and recurrent MMR deficient and proficient endometrial carcinoma.
    Di Dio C; Bogani G; Di Donato V; Cuccu I; Muzii L; Musacchio L; Scambia G; Lorusso D
    Gynecol Oncol; 2023 Feb; 169():27-33. PubMed ID: 36493574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current status of treatment with immune checkpoint inhibitors for gastrointestinal, hepatobiliary, and pancreatic cancers.
    Eso Y; Seno H
    Therap Adv Gastroenterol; 2020; 13():1756284820948773. PubMed ID: 32913444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Latest evidence on immune checkpoint inhibitors in metastatic colorectal cancer: A 2022 update.
    Boukouris AE; Theochari M; Stefanou D; Papalambros A; Felekouras E; Gogas H; Ziogas DC
    Crit Rev Oncol Hematol; 2022 May; 173():103663. PubMed ID: 35351582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunotherapy in Hepatogastroenterology - update 2022: efficacy and immune-related adverse events].
    Krimmel L; Quante M; Bengsch B
    Dtsch Med Wochenschr; 2023 Mar; 148(6):294-300. PubMed ID: 36878227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expanding the Scope of Immunotherapy in Colorectal Cancer: Current Clinical Approaches and Future Directions.
    Kreidieh M; Mukherji D; Temraz S; Shamseddine A
    Biomed Res Int; 2020; 2020():9037217. PubMed ID: 32090113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer.
    Rizzo A; Ricci AD; Brandi G
    Cancers (Basel); 2021 Feb; 13(3):. PubMed ID: 33535621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic treatment options for advanced biliary tract carcinoma.
    Xie C; McGrath NA; Monge Bonilla C; Fu J
    J Gastroenterol; 2020 Oct; 55(10):944-957. PubMed ID: 32748173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The State of Immunotherapy in Hepatobiliary Cancers.
    Ilyas FZ; Beane JD; Pawlik TM
    Cells; 2021 Aug; 10(8):. PubMed ID: 34440865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarkers for response to immunotherapy in hepatobiliary malignancies.
    Lin ZF; Qin LX; Chen JH
    Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):413-419. PubMed ID: 35973935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in Targeted Immunotherapy for Hepatobiliary Cancers.
    Ruff SM; Shannon AH; Pawlik TM
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent progress and current challenges of immunotherapy in advanced/metastatic esophagogastric adenocarcinoma.
    Moehler M; Högner A; Wagner AD; Obermannova R; Alsina M; Thuss-Patience P; van Laarhoven H; Smyth E
    Eur J Cancer; 2022 Nov; 176():13-29. PubMed ID: 36183651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients.
    Ziogas IA; Evangeliou AP; Giannis D; Hayat MH; Mylonas KS; Tohme S; Geller DA; Elias N; Goyal L; Tsoulfas G
    Oncologist; 2021 Jun; 26(6):e1036-e1049. PubMed ID: 33314549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of immunotherapy in the management of hepatocellular carcinoma: current standards and future directions.
    Weinmann A; Galle PR
    Curr Oncol; 2020 Nov; 27(Suppl 3):S152-S164. PubMed ID: 33343209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.